MUNDIPHARMA
16.4.2024 11:01:35 CEST | Business Wire | Press release
Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work. The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416962162/en/
The product is an established pressurised metered-dose inhaler (pMDI) for the treatment of asthma, where the use of a combination product is appropriate, and has been available on the market for more than a decade.3
It currently uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant.3 European Union regulation on these types of gases aims to reduce their use, and therefore their emissions, by two-thirds by 2030.1
Work is already under way to source an alternative to the HFA-227 gas used in fluticasone propionate/formoterol fumarate pMDI. This new collaboration will revitalise the efforts to identify and switch to a more environmentally friendly propellant. If successful, this will result in a significantly lower impact on global warming and alignment with European Union regulation on fluorinated greenhouse gases.1
With more than 262 million people living with asthma globally, the reformulation of some asthma treatments to reduce carbon emissions could have a significant impact on the global carbon footprint.4,5
“We are dedicated to positively influencing the life of asthma patients across the globe. This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler. We are determined to achieve this before the European Union ban of HFA (hydrofluoroalkane) gases comes into effect, and our collaboration with Vectura demonstrates this, as well as our aim to an overall commitment to sustainable healthcare innovation,” said Yuri Martina, Chief Development and Medical Officer at Mundipharma.
“At Vectura, our priority is to ensure that patients prescribed fluticasone propionate/formoterol fumarate pMDI can continue to have access to this treatment. Using Vectura’s expertise and extensive track record in the development of inhaled prescription medicines and devices, we believe the collaboration with Mundipharma will enable us to meet our environmental responsibilities and enable patients to use fluticasone propionate/formoterol fumarate pMDI in the years to come,” said Geraldine Venthoye, Chief Scientific Officer, Vectura.
®: FLUTIFORM is a registered trademark of Jagotec AG used under licence by Mundipharma.
References
- Regulation (EU) No 517/2014 of the European Parliament and of the Council of 16 April 2014 on fluorinated greenhouse gases and repealing Regulation (EC) No 842/2006 Text with EEA relevance. Available at: https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=uriserv:OJ.L_.2014.150.01.0195.01.ENG (last accessed March 2024)
- flutiform® pMDI emissions manufacturing data, Q4 2022 – Q4 2023. Data on file.
- flutiform® Summary of Product Characteristics (SmPC). Last updated 13 April 2022. https://www.emcpi.com/pi/26954. (last accessed April 2024).
- Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22
- NHS England, World Asthma Day: tackling climate change and improving respiratory care. Available at https://www.england.nhs.uk/blog/world-asthma-day-tackling-climate-change-and-improving-respiratory-care/ (last accessed March 2024)
*ENDS*
Job code: SciA-FLU-2400001| Date of preparation: April 2024
|
Notes to Editors
About flutiform® (fluticasone propionate/formoterol fumarate):
flutiform® is an inhaler (a pressurised metered-dose inhalation, suspension) which contains two active ingredients, fluticasone propionate and formoterol fumarate dihydrate.3 This fixed-dose combination of fluticasone propionate and formoterol fumarate (flutiform®) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β₂ agonist) is appropriate for the management of asthma symptoms.3
About Mundipharma:
Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East.
Mundipharma is dedicated to bringing innovative treatments to patients in the areas of respiratory, pain management, infectious disease as well as other severe and debilitating disease areas. Our guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything we do. For more information visit www.mundipharma.com.
About Vectura:
Vectura is a specialist inhalation contract development and manufacturing organization (CDMO) that provides inhaled drug development solutions to help customers bring their medicines to patients. With 25 years’ experience, it provides a combination of formulation science, device technology, and inhaled development expertise. Vectura is a member of the Vectura Fertin Pharma group of companies. For more information visit www.vectura.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416962162/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Toluna Appoints Amy Fenton as Chief Executive Officer14.10.2026 15:30:00 CEST | Press release
Appointment completes the planned succession announced on October 8, 2026. Founder Frédéric Charles Petit continues as Board member, Senior Advisor and Shareholder. Toluna, a global leader in consumer insights and market research technology, today announces the appointment of Amy Fenton as Chief Executive Officer, effective October 15, 2026. Ms. Fenton succeeds Frédéric Charles Petit, who founded Toluna and has led the company for 25 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014103169/en/ Amy Fenton appointed as new Chief Executive Officer, Toluna The appointment concludes the structured succession process announced on October 8, 2026, led by the Board in close consultation with Mr. Petit and supported by a leading executive search firm. Ms. Fenton brings more than 30 years of leadership experience in the insights and analytics industry. She joins Toluna from MarketCast, where she served as Chief Executive Off
BanyanGlobal Family Business Advisors Named Family Business Advisory Practice of the Year at the STEP Private Client Awards for the Fourth Time14.10.2026 15:05:00 CEST | Press release
The international recognition, also awarded to the firm in 2018, 2020 and 2021, honors Banyan's approach of pairing governance with the skills and confidence families need for long-term ownership BanyanGlobal Family Business Advisors ("Banyan") has been named Family Business Advisory Practice of the Year at the 21st annual STEP Private Client Awards, one of the most respected international honors in the private client profession. It is the fourth time Banyan has won the category, following wins in 2018, 2020 and 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013883351/en/ Kelly Greig, STEP Board Member and Dennis Jaffe, BanyanGlobal Family Business Advisors at the awards ceremony. BanyanGlobal won the Family Business Advisory Practice of the Year at the 21st Annual STEP Private Client Awards. The independent judging panel singled out Banyan's approach: "BanyanGlobal Family Business Advisors has redefined family busi
Telekom Srbija Group Expands AI Investment and Strengthens U.S. Technology Partnerships14.10.2026 15:02:00 CEST | Press release
Leading Southeast European Telecommunications and Technology Group Advances AI Innovation Through International Collaboration, Startup Investments and 5G Infrastructure. Following the October 1 agreement between Serbia and the United States to strengthen cooperation in artificial intelligence (AI), Telekom Srbija Group is expanding its AI investment and deepening relationships with leading U.S. technology companies as part of its strategy to develop the next generation digital services. As part of these efforts, Telekom Srbija Group has engaged with the U.S. State Department, Department of Commerce and Export-Import Bank to explore opportunities for technology cooperation and project financing, with the ambition of becoming a preferred regional partner for U.S. companies. “Artificial intelligence represents one of the greatest opportunities for the future of telecommunications and digital services,” said Vladimir Lučić, CEO of Telekom Srbija Group. “We have been investing in this techn
Lenovo Uncovers What Happens When Entrepreneurs Look Beyond Borders for Support14.10.2026 15:00:00 CEST | Press release
New documentary series follows small business founders from around the world as unexpected connections and technology spark fresh ideas, new approaches to business challenges and opportunities for growth Today, Lenovo debuts the first episode of its new documentary series from Backing Every Business, its global initiative designed to connect small businesses with the people, technology and support they need to grow and thrive. The series features five businesses participating in Twinning, Lenovo’sprogram that brings small business founders from around the world together, connecting them through mentorship across shared growth goals, access to resources including technology, AI training, funding designed to help address real business challenges and turn new ideas into action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014736241/en/ The four-part series follows entrepreneurs from Japan, Mexico, the U.K. and the U.S. as
Wolters Kluwer names Alberto de Benito Aznar General Manager of Audit & Assurance14.10.2026 15:00:00 CEST | Press release
Experienced Wolters Kluwer executive returns to the business as it expands its integrated assurance platform and advances its AI strategy Wolters Kluwer, a global leader in professional information, software solutions and services, today announced the appointment of Alberto de Benito Aznar as General Manager of its Audit & Assurance business, part of the Corporate Performance & ESG division. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014786222/en/ De Benito Aznar returns to a business and market he knows well. He began his Wolters Kluwer career more than 10 years ago in Corporate Strategy and subsequently led operations for Audit & Assurance before serving most recently as General Manager of Corporate Tax. “Alberto brings a strong combination of strategic, operational and commercial leadership to Audit & Assurance,” said Maria Montenegro, CEO of Corporate Performance & ESG at Wolters Kluwer. “His leadership of Corpora
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom